Atypical antipsychotics have been indirectly associated with the diagnosis of type 2 diabetes mellitus (T2DM) in patients with schizophrenia. The purpose of this cross-sectional study was to determine the prevalence of T2DM and to examine the risk factors associated with T2DM among outpatients diagnosed with schizophrenia. The study also sought to determine which risk factors are of particular screening importance in monitoring the metabolic status of these patients.
Methods
This study included 202 patients diagnosed with schizophrenia. Data on a number of known and hypothesized risk factors for T2DM were collected.
Results
Risk factors for T2DM identified by bivariate analyses in this sample included older age, waist-to-hip ratio >1.0, sedentary lifestyle, number of hours worked per week, hyperlipidemia, previous screening for T2DM, higher random blood glucose, and number of years on atypical antipsychotics risperidone or olanzapine. However, further scrutiny using multiple logistic regression identified only sedentary lifestyle, waist-to-hip ratio ≥1.0, and a diagnosis of hyperlipidemia as significant risk factors in these patients. Similar to other studies, there was an 11.5% (22/192) lifetime prevalence rate of diabetes among this population.
Conclusions
Risk factors traditionally associated with T2DM, as well as waist-to-hip ratio, are the factors most strongly associated with increased risk of diabetes in patients with schizophrenia.
HossainP, KawarB, El NahasM.Obesity and diabetes in the developing world—a growing challenge. N Engl J Med. 2007;356:213–215.
2.
AdamsPF, MaranoMA.Current estimates from the National Health Interview Survey, 1994. Vital Health Stat. 1995;193:1–260.
3.
PleisJR, Lethbridge-ÇejkuM.Summary health statistics for U.S. adults: National Health Interview Survey, 2006. Vital Health Stat 10. 2007;235:1–153.
4.
HarrisMI.Undiagnosed NIDDM: clinical and public health issues. Diabetes Care. 1993;16:642–652.
5.
CowieCC, RustKF, Byrd-HoltDD, . Prevalence of diabetes and impaired fasting glucose in adults in the U. S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care. 2006;29:1263–1268.
6.
DynesJB.Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis Nerv Syst. 1969;30:341–344.
DixonL, WeidenP, DelahantyJ, . Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26:903–912.
10.
GoffDC, SullivanLM, McEvoyJP, . A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45–53.
11.
MukherjeeS, SchnurDB, ReddyR.Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989;1:495.
12.
HolmbergSK, KaneC.Health and self-care practices of persons with schizophrenia. Psychiatr Serv. 1999;50:827–829.
13.
BrownS, BirtwistleJ, RoeL, . The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697–701.
14.
LundBC, PerryPJ, BrooksJM, . Clozapine use in patients with schizophrenia and the risk of diabetes. Arch Gen Psychiatry. 2001;58:1172–1176.
15.
CaroJJ, WardA, LevintonC, . The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002;63:1135–1139.
16.
KornegayCJ, Vasilakis-ScaramozzaC, JickH.Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry. 2002;63:758–762.
17.
KoroCE, FedderDO, L'ItalienGJ, . Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325:243.
18.
SernyakMJ, LeslieDL, AlarconRD, . Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561–566.
19.
FullerMA, ShermockKM, SecicM, . Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy. 2003;23:1037–1043.
20.
GianfrancecsoF, WhiteR, WangRH, . Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol. 2003;23:328–335.
KollerEA, WeberJ, DoraiswamyPM, . A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry. 2004;65:857–863.
25.
AllisonDB, MentoreJL, HeoM, . Antipsychotic- induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–1696.
26.
McEvoyJP, MeyerJM, GoffDC, . Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19–32.
27.
HaggS, LindblomY, MjörndalT, . High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol. 2006;21:93–98.
28.
MeyerJ, LohC, LeckbandSG, . Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract. 2006;12:5–10.
29.
De HertMA, van WinkelR, van EyckD, . Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87–93.
30.
KoroCE, FedderDO, L'ItalienGJ, . An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59:1021–1026.
31.
AtmacaM, KulogluM, TezcanE, . Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64:598–604.
32.
LindenmayerJP, CzoborP, VolavkaJ, . Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160:290–296.
33.
LiebermanJA, StroupTS, McEvoyJP, . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.
34.
StroupTS, LiebermanJA, McEvoyJP, . Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611–622.
35.
MortensenPB, JuelK.Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry. 1993;163:183–189.
36.
HarrisEC, BarracloughB.Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53.
37.
HennekensCH, HennekensAR, HollarD, . Schizophrenia and increased risks of cardiovascular disease. Am Heart J.2005;150:1115–1121.
38.
American Diabetes Association. Position statement: screening for diabetes. Diabetes Care.2002;25:(suppl 1)S21–24.
39.
CohnTA, SernyakMJ.Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry. 2006;51:492–501.
40.
RolkaDB, NarayanKMV, ThomsonTJ, . Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care. 2001;24:1899–1903.
41.
World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO consultation.Geneva, Switzerland: Department of Non-Communicable Disease Surveillance, World Health Organization; 1999.
42.
ThakoreJH, MannJN, VlahosI, . Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord. 2002;26:137–141.
43.
RyanMC, FlanaganS, KinsellaU, . The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci. 2004;74:1999–2008.
44.
American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31:(suppl 1)S12–64.
45.
PerryPJ, ArgoTR, CarnahanRM, . The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol. 2005;25:1–5.
46.
JinH, MeyerJM, JesteDV.Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59–64.
47.
NewcomerJW.Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68:(suppl 1)20–27.
